secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000914475-22-000043
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q2 INGREZZA sales $350M (+32%), raises FY guidance to $1.35-1.40B; essential tremor Phase 2a fails
--------------------------------------------------------------------------------

- GAAP net loss $16.9M ($0.18 loss per diluted share) vs net income $42.3M in Q2 2021, largely due to $70M debt extinguishment loss.
- Non-GAAP net income $82.1M ($0.84 EPS) vs $70.1M ($0.72); INGREZZA net product sales $350M, up 32% YoY.
- Raised 2022 INGREZZA net product sales guidance to $1.35-1.40B from prior $1.30-1.35B; GAAP R&D guidance $415-450M.
- Phase 2a study of NBI-827104 in essential tremor did not meet endpoints; company discontinues development in that indication.
- Received $20M milestone from MTPC for DYSVAL launch in Japan; FDA cleared IND for NBI-1117568 (M4 agonist for schizophrenia) Phase 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000043/0000914475-22-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000043/nbix-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000914475-22-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer